Collaboration and License Option Agreement Sample Contracts

Contract

Collaboration and License Option Agreement • September 8th, 2020

• Contract Type
  Collaboration and License Option Agreement
• Filed
  September 8th, 2020

Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement

Collaboration and License Option Agreement • January 24th, 2024

• Contract Type
  Collaboration and License Option Agreement
• Filed
  January 24th, 2024

• A new public-private collaboration aims to discover new active agents for treatment and prophylaxis of infections of immunocompromised patients.

Portions of this exhibit marked [*] are requested to be treated confidentially. COLLABORATION AND LICENSE OPTION AGREEMENT

Collaboration and License Option Agreement • April 8th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • Indiana

• Contract Type
  Collaboration and License Option Agreement
• Filed
  April 8th, 2010
• Company
  Furiex Pharmaceuticals, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Indiana

This Collaboration and License Option Agreement (“Agreement”) is effective as of February 10, 2009 (“Effective Date”). The parties to this Agreement are Eli Lilly and Company having its principal offices at Lilly Corporate Center, Indianapolis, IN 46285 (“Lilly”), and Magen BioSciences, Inc., having its principal offices at 100 Beaver St., Suite 101, Waltham, MA 02453 (“Magen”). Lilly and Magen may be referred to herein individually as a “Party”, and collectively as the “Parties”.